Please login to the form below
Abivax
This page shows the latest Abivax news and features for those working in and with pharma, biotech and healthcare.
Abivax’s COVID-19 study declared Research National Priority by French government
Abivax is devoting significant efforts to this major international clinical trial and simultaneously accelerating ABX464 manufacturing scale-up for potential 2021 commercialisation,” he added. ... In July, Abivax treated the first patient in the phase
Latest news
-
AbbVie, Amgen and Takeda team up for joint COVID-19 trial
French biotech company Abivax is also currently investigating its experimental ulcerative colitis drug ABX464 as an early treatment for elderly or high-risk patients with COVID-19.
-
Roche’s Actemra fails in late-stage severe COVID-19 study
Another anti-inflammatory drug, ABX464, is currently being studied by Abivax as an early treatment for elderly or high-risk patients with confirmed COVID-19.
-
Mesoblast expands compassionate use COVID-19 programme
A host of candidates are being investigated to regulate the overactive inflammatory side effects associated with some cases of COVID-19, including Abivax’s experimental anti-inflammatory med ABX464. ... Last week, Abivax initiated a phase 2b/3 study
-
Abivax doses first patient in phase 2b/3 COVID-19 clinical trial
Study will evaluate experimental anti-inflammatory drug. French biotech company Abivax has treated the first patient in a phase 2b/3 study of its experimental anti-inflammatory drug ABX464 in ... Currently, Abivax has received approval for studies in
-
Trial data suggest Abivax’ drug may clear latent HIV
The drug reduced HIV DNA in cells over 28 days. French biotech Abivax has new data for its HIV drug candidate ABX464 that suggest it may suppress latent HIV in reservoirs – ... Those anti-inflammatory properties have encouraged Abivax to carry out a
AbbVie, Amgen and Takeda team up for joint COVID-19 trial
Roche’s Actemra fails in late-stage severe COVID-19 study
Mesoblast expands compassionate use COVID-19 programme
Abivax doses first patient in phase 2b/3 COVID-19 clinical trial
More from news
Approximately 3 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
The race for a HIV ‘cure’
Another company working on a similar candidate is French biotech Abivax.
The race for a HIV ‘cure’
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Midweight-Senior Creative
-
Competitive Salary Offered
-
Digital account director
-
Competitive
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Understanding the ‘real world’ starts and ends with the patient
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- Biogen and Eisai present new data for controversial Alzheimer's drug Aduhelm at AAIC
- CONGREGO™ IS NOW MULTI-PLATFORM
- Onyx Health Marks Record Growth with Six New Appointments
- FDA expands use of COVID-19 antibody cocktail
- New European supply deals show Pfizer and Moderna have increased COVID-19 vaccine prices
- Ipsen’s spending spree bolsters neurology pipeline
- AMICULUM® launches Cence, a new specialist publications agency
- The future of office working designed with our people in mind: ‘Work Where You Work Best’, an Evoke KYNE model
- GSK, Vir’s sotrovimab cuts hospitalisation and death risk by 79% in COVID-19 outpatients
- Biogen and Ionis post ‘encouraging’ early results for Alzheimer’s disease candidate
- Eylea set to challenge Lucentis in UK after NICE recommendation
- Onyx Health Launch Creative Studio After Record Year
- BioNTech to use mRNA technology to develop a ‘highly effective’ malaria vaccine
PMHub
Six Degrees Medical Consulting
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...
Latest intelligence
- Guide
- How to embrace behavioural science principles in healthcare MR...
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
